Key Highlights: Implications: Piramal Pharma’s move to 74% ownership of Yapan Bio for ₹76 crore turns the Hyderabad CDMO into a subsidiary, giving Piramal tighter control over Yapan’s process developm...
Key Highlights: Implications: Biodeal’s ₹385 crore raise gives it the capital to scale up manufacturing, add new products, and enter more regulated markets, which should help it win bigger, longer-ter...
Key Highlights: Implications: The deal adds ~$90–100 million of annualized revenue visibility from 2029, diversifies Gland’s customer base, and strengthens its credibility as a o...
Key Highlights: Implications: The new cGMP/US FDA/EU-compliant suite at Gland’s Visakhapatnam JNPC site, adding ~1,400 kg/year of sterile API capacity, should help both companies capture m...
Key Highlights: Implications: The expansion makes Turbhe more competitive for high-potency peptides, HPAPIs, and biomolecules, helping Piramal attract programs that need safe, sm...
Key Highlights: Implications: If completed, the transaction would likely be a strong validation event for mid-sized Indian pharmaceutical businesses that combine branded generics, nu...
Key Highlights: Implications: By selling the Roorkee and Noida plants (for around ₹56 crore) but retaining brands, trademarks, its Beauty Entrepreneur network, and all commercial operation...
